Actively Recruiting

Age: 65Years +
All Genders
NCT05337631

Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy

Led by University Hospital Freiburg · Updated on 2025-03-25

1500

Participants Needed

18

Research Sites

291 weeks

Total Duration

On this page

Sponsors

U

University Hospital Freiburg

Lead Sponsor

C

Charite University, Berlin, Germany

Collaborating Sponsor

AI-Summary

What this Trial Is About

The number of elderly head-and-neck squamous cell carcinoma (HNSCC) patients is increasing; however, the evidence regarding the ideal treatment for this often vulnerable and frail patient cohort is limited. Although the benefit of concomitant chemotherapy has been reported to decrease in elderly HNSCC patients based on the MACH-NC meta-analysis, it remains unknown whether state-of-the art radiotherapy techniques such as intensity-modulated radiotherapy (IMRT), modern supportive treatments and alternative chemotherapy fractionation (e.g., cisplatin weekly) may have altered this observation. The objective of this retrospective multinational multicenter study is to determine the oncological outcomes of elderly patients (≥65 years) with locally advanced HNSCCs undergoing definitive (chemo-)radiation and to investigate the influence of concomitant chemotherapy on overall survival and progression-free survival after adjusting for potential confounder variables such as age, performance status and comorbidity burden.

CONDITIONS

Official Title

Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy

Who Can Participate

Age: 65Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Definitive (chemo-)radiotherapy for locally advanced head-and-neck squamous cell carcinoma (HNSCC) of the oral cavity, oropharynx, hypopharynx, or larynx
  • Primary treatment started since 2005
  • Age 65 years or older at the time of (chemo-)radiotherapy
Not Eligible

You will not qualify if you...

  • Receiving adjuvant (chemo-)radiotherapy
  • History of previous head-and-neck cancers or prior radiotherapy in the head-and-neck region
  • Presence of distant metastases at the start of (chemo-)radiotherapy (cM1)
  • HNSCC of the nasopharynx, salivary glands, skin, or unknown primary site

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 18 locations

1

Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine

Baltimore, Maryland, United States, 21287

Completed

2

Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai

New York, New York, United States, 10017

Completed

3

Department of Radiation Oncology, Case Western Reserve University

Cleveland, Ohio, United States, 10900

Completed

4

Division of Radiation Oncology, The Ohio State University Wexner

Columbus, Ohio, United States, 43201

Completed

5

Radiation Oncology Department, German Oncology Center

Limassol, Cyprus

Completed

6

Brno University Hospital

Brno, Czechia

Completed

7

Department of Radiooncology and Radiotherapy, Charité-Universitätsmedizin Berlin

Berlin, Germany

Completed

8

Department of Radiation Oncology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg

Erlangen, Germany

Completed

9

Department of Radiotherapy and Oncology, Goethe-University Frankfurt am Main

Frankfurt, Germany

Completed

10

University of Giessen

Giessen, Germany

Completed

11

Martin-Luther-Universität Halle-Wittenberg

Halle, Germany

Completed

12

Jena University Hospital

Jena, Germany

Actively Recruiting

13

Department of Radiation Oncology, University Hospital Schleswig-Holstein

Kiel, Germany

Completed

14

Department of Radiation Oncology, University Medical Center Leipzig

Leipzig, Germany

Completed

15

Department of Radiation Oncology, University Medical Center Mainz

Mainz, Germany

Completed

16

Department of Radiation Oncology, University Hospital, LMU Munich

Munich, Germany

Completed

17

Department of Radiation Oncology, University Hospital Würzburg

Würzburg, Germany

Completed

18

Department of Radiation Oncology, University Hospital Zurich (USZ), University of Zurich (UZH)

Zurich, Switzerland

Completed

Loading map...

Research Team

A

Alexander Rühle, MD, MHBA

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here